Farley did not elaborate on his views, but he is hardly the only Fortune 500 CEO who believes AI could spell trouble for ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

September/October 2021, Paper: "On November 30, 2020, Moderna Therapeutics announced that Phase III clinical trials for its messenger RNA vaccine demonstrated 95% protective efficacy against the ...

The vaccine was previously only licensed for adults aged 60 years and older. “RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...